These innovative compounds represent a significant leap in the management of type 2 diabetes. Retatrutide, a combined GLP-1 and GIP receptor agonist, demonstrates promising efficacy in lowering blood glucose levels. https://jemimakcog355607.blogsmine.com/39459155/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide